Current Treatment Guidelines of SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children: A Literature Review and Expert Opinion

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a systemic disorder that seems to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since April 2020, there have been multiple reports about children with this new condition worldwide, including Europe, Asia, Latin America, and North America. The symptoms of this syndrome mimic the clinical manifestations of Kawasaki disease; therefore, the treatment of Kawasaki disease, as well as supportive care, was the management of choice in children with MIS-C in the early days of recognizing it. It is important to precisely ascertain the risk of COVID-19 infection and its severity in children and to acknowledge the management of this syndrome, with reliable data from cohorts, trials, and experts' opinions. In the current review, we summarize the current management guidelines for MIS-C and present our own protocol to answer some clinical questions regarding MIS-C management during the COVID-19 pandemic.

Keywords

COVID-19 - SARS-CoV-2 - multisystem inflammatory syndrome in children - treatment - guideline

Publikationsverlauf

Eingereicht: 04. Februar 2021

Angenommen: 09. April 2021

Artikel online veröffentlicht:
22. Juni 2021

• References

• 1 Ghodsi A, Azarfar A, Ghahremani S. A review of coronavirus disease (COVID-19) in children. J Pediatr Neurol 2020;8(03):
• 2 Farhat AS, Sayedi SJ, Akhlaghi F, Hamedi A, Ghodsi A. Coronavirus (COVID-19) infection in newborns. Int J Pediatr 2020; 8 (06) 11513-11517
• 3 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
• 4 Gorbalenya AE, Baker SC, Baric R. et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the Coronavirus Study Group. BioRxiv 2020
• 5 Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr 2018; 6: 198
• 6 Turnier JL, Anderson MS, Heizer HR, Jone P-N, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015; 136 (03) e609-e614
• 7 Catalano-Pons C, Quartier P, Leruez-Ville M. et al. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin Infect Dis 2005; 41 (05) e53-e56
• 8 Whittaker E, Bamford A, Kenny J. et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324 (03) 259-269
• 9 Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel) 2020; 7 (07) 69
• 10 Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19: The Royal College of Paediatrics and Child Health. Accessed 2020 at: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims
• 11 World Health Organization Scientif Brief. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Accessed 2020 at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
• 12 Health Alert Network (HAN). Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Accessed 2019 at: https://emergency.cdc.gov/han/2020/han00432.asp
• 13 McCrindle BW, Rowley AH, Newburger JW. et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135 (17) e927-e999
• 14 Newburger JW, Takahashi M, Gerber MA. et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110 (17) 2747-2771
• 15 Verdoni L, Mazza A, Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395 (10239): 1771-1778
• 16 Toubiana J, Poirault C, Corsia A. et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094
• 17 Cheung EW, Zachariah P, Gorelik M. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020; 324 (03) 294-296
• 18 Belhadjer Z, Méot M, Bajolle F. et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020
• 19 Kanegaye JT, Wilder MS, Molkara D. et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123 (05) e783-e789
• 20 Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005; 191 (04) 492-498
• 21 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191 (04) 499-502
• 22 Ghodsi A, Malek A, Ghahremani S. A review of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Hormozgan Medical J 2020;24(04):
• 23 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med 2020; 383 (04) 334-346
• 24 Zou H, Lu J, Liu J. et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis 2021; 102: 319-326
• 25 Shulman S. Pediatric COVID-associated multi-system inflammatory syndrome (PMIS). J Pediat Inf Disc Soc 2020;
• 26 Ghodsi A, Mahmoudabadi E, Ghahremani S, Malek A. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection. Arch Pediatr Infect Dis 2021;
• 27 Grimaud M, Starck J, Levy M. et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020; 10 (01) 69
• 28 Venturini E, Montagnani C, Garazzino S. et al; Italian SITIP-SIP SARS-Cov-2 pediatric infection study group. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr 2020; 46 (01) 139
• 29 Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Accessed 2020 at: https://www.cdc.gov/mis-c/hcp/
• 30 American academy of pediatrics. Accessed 2019 at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
• 31 Ziaee V, Assari R, Mamishi S. et al. An algorithmic approach to multisystem inflammatory syndrome in children with COVID-19: Tehran Children's Medical Center Protocol. Iran J Pediatr 2020;30(05):
• 32 children's hospital of philadelphia guideline. Accessed 2020 at: https://www.chop.edu/clinical-pathway/multisystem-inflammatory-syndrome-mis-c-clinical-pathway
• 33 Alhazzani W, Møller MH, Arabi YM. et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46 (05) 854-887
• 34 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
• 35 Chiotos K, Bassiri H, Behrens EM. et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc 2020
• 36 Deza Leon MP, Redzepi A, McGrath E. et al. COVID-19–associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020; 9 (03) 407-408
• 37 Hennon TR, Penque MD, Abdul-Aziz R. et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020; 101232
• 38 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020; 72 (11) 1791-1805
• 39 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. version 2. Arthritis Rheumatol 2020;
• 40 Capone CA, Subramony A, Sweberg T. et al; Northwell Health COVID-19 Research Consortium. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. J Pediatr 2020; 224: 141-145
• 41 Ouldali N, Toubiana J, Antona D. et al; French Covid-19 Paediatric Inflammation Consortium. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 2021; 325 (09) 855-864
• 42 Jiang L, Tang K, Levin M. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20 (11) e276-e288
• 43 Chiotos K, Hayes M, Kimberlin DW. et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020
• 44 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020
• 45 Loke Y-H, Berul CI, Harahsheh AS. Multisystem inflammatory syndrome in children: is there a linkage to Kawasaki disease?. Trends Cardiovasc Med 2020; 30 (07) 389-396
• 46 Zhao J-Y, Yan J-Y, Qu J-M. Interpretations of “diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)”. Chin Med J (Engl) 2020; 133 (11) 1347-1349
• 47 Kobayashi T, Saji T, Otani T. et al; RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379 (9826): 1613-1620
• 48 Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2017; 1 (01) CD011188
• 49 Horby P, Landrain M. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Nuffield Dept Population Health; Accessed 2020 at: https://www.remapcap.org/covid19publications/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
• 50 Horby P, Mafham M, Linsell L. et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxiv 2020
• 51 Hadjadj J, Yatim N, Barnabei L. et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. MedRxiv 2020
• 52 Trouillet-Assant S, Viel S, Gaymard A. et al; COVID HCL Study group. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020; 146 (01) 206-208.e2